Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)

[1]  Rodolfo Ghirlando,et al.  CTCF: making the right connections , 2016, Genes & development.

[2]  Katrina H. Smith,et al.  Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. , 2015, Neuro-oncology.

[3]  D. Haussler,et al.  The UCSC Genome Browser database: 2015 update , 2014, Nucleic Acids Res..

[4]  N. Galjart,et al.  CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin , 2014, Nucleic acids research.

[5]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Xinjian Peng,et al.  PC3-Secreted Microprotein Is a Novel Chemoattractant Protein and Functions as a High-Affinity Ligand for CC Chemokine Receptor 2 , 2014, The Journal of Immunology.

[7]  David Haussler,et al.  ENCODE Data in the UCSC Genome Browser: year 5 update , 2012, Nucleic Acids Res..

[8]  H. Hurwitz,et al.  Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors , 2012, Cancer Chemotherapy and Pharmacology.

[9]  R. Beroukhim,et al.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma , 2012, Journal of Neuro-Oncology.

[10]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[11]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[12]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[13]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Liz Y. Han,et al.  Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer , 2008 .

[16]  Arjan W. Griffioen,et al.  Tumour vascularization: sprouting angiogenesis and beyond , 2007, Cancer and Metastasis Reviews.

[17]  H. Lilja,et al.  A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue , 2007, Biological chemistry.

[18]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[19]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[20]  Eun-Joung Moon,et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.

[21]  C. Bucana,et al.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. , 1998, Journal of the National Cancer Institute.

[22]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[23]  B. Sikic,et al.  Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. , 1991, Cancer research.

[24]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[25]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[26]  Liz Y. Han,et al.  Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. , 2008, Neoplasia.